QuidelOrtho Corp (QDEL)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$33.11
Buy
$36.95
$-1.96 (-5.52%)
Prices updated at 14 May 2025, 09:07 EDT
| Prices minimum 15 mins delay
Prices in USD
Quidel Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. It includes applications in infectious diseases, women's health, gastrointestinal diseases, and others.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Medical Devices
Chairman
Dr. Kenneth F. Buechler, PhD
CEO
Mr. Brian J. Blaser
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
6,600
Head office
9975 Summers Ridge Road
San Diego
United States
92121
Key personnel
Owner name | Salary |
---|---|
Ms. Evelyn S. Dilsaver Independent Director | 0.07m |
Mr. Edward L. Michael Independent Director | 0.09m |
Dr. Kenneth F. Buechler, PhD Chairman of the Board | 0.16m |
Dr. Mary Lake Polan, M.D.,PhD Independent Director | 0.07m |
Mr. Richard Scott Huennekens Independent Director | - |
Ms. Ann D. Rhoads Independent Director | 0.10m |
Mr. Joseph M. Busky Chief Financial Officer and Principal Accounting Officer | 0.59m |
Dr. Matthew W. Strobeck, PhD Independent Director | 0.07m |
Mr. John R. Chiminski Independent Director | - |
Mr. Brian J. Blaser Director, President and Chief Executive Officer | 0.63m |
Dr. Kenneth J. Widder, M.D. Independent Director | 0.09m |
Ms. Michelle A. Hodges, J.D. Chief Legal Officer and Corporate Secretary | 0.54m |
Mr. Joseph D. Wilkins, Jr Independent Director | 0.07m |
Mr. Ronald Lee Bowman Chief Human Resources Officer | - |
Mr. Jonathan Philip Siegrist Executive Vice President, Research and Development and Chief Technology Officer | 0.12m |
Mr. Philip D. McLellan Chief Operations Officer | 0.41m |
Top 5 shareholders
Owner name | No. of shares |
---|---|
T. Rowe Price Investment Management,Inc. | 11,238,826 |
BlackRock Inc | 8,440,415 |
BlackRock, Inc. | 7,273,484 |
T. Rowe Price | 7,229,788 |
Vanguard Group Inc. ( Junked) | 6,819,139 |
Director dealings
Date | Action |
---|---|
11 Dec 2024 | - |
01 Dec 2024 | - |
01 Dec 2024 | - |
01 Dec 2024 | - |
18 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
08 Nov 2024 | - |
15 Oct 2024 | - |
15 Oct 2024 | - |
15 Oct 2024 | - |
15 Oct 2024 | - |
15 Oct 2024 | - |
15 Oct 2024 | - |
15 Sep 2024 | - |
14 Sep 2024 | - |
14 Sep 2024 | - |
14 Sep 2024 | - |
28 Jul 2024 | - |
28 Jul 2024 | - |
Please note that past performance is not a reliable indicator of future returns.